Alzinova AB is a biopharma company dedicated to developing both active and passive immunotherapies to treat Alzheimer’s disease. The company was founded by scientists at the University of Gothenburg, Sweden, in 2011 after the invention of a unique technology platform, AβCC. The AβCC technology specifically stabilises disease-driving oligomers of the peptide amyloid-β (Aβ), thus enabling the development of disease-modifyi...
Alzinova AB is a biopharma company dedicated to developing both active and passive immunotherapies to treat Alzheimer’s disease. The company was founded by scientists at the University of Gothenburg, Sweden, in 2011 after the invention of a unique technology platform, AβCC. The AβCC technology specifically stabilises disease-driving oligomers of the peptide amyloid-β (Aβ), thus enabling the development of disease-modifying therapeutics. Business angels and the holding company at the University of Gothenburg, GU Holding AB (now GU Ventures AB), provided seed capital and business development support during the early years.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.